Arena Pharmaceuticals, inc (ARNA) Q2 2021 Earnings Call Transcript fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Alnylam Pharmaceuticals Q2 2021 Earnings Call. [Operator Instructions]
I would now like to turn the call over to your host, Christine Lindenboom. You may begin.
Christine Regan Lindenboom
Senior Vice President, Investor Relations and Corporate Communications
Good morning. I m Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications at Alnylam. With me today on the phone are John Maraganore, Chief Executive Officer; Tolga Tanguler, Chief Commercial Officer; Akshay Vaishnaw, President of R&D Jeff Poulton, Chief Financial Officer; and Yvonne Greenstreet, President and Chief Operating Officer. For those of you participating via conference call, the accompanying slides can be accessed by going to the Events section of the Investors page of our website, investors.alnylam.com/events. During today s call, as outlined in Slide 2, John will provide some introductory remark
Operator
I would now like to turn the call over to the CARA team. Please proceed.
Jack Hildick-Smith
Investor Relations
Good afternoon, this is Jack Hildick-Smith with Stern Investor Relations and welcome to Cara Therapeutics first quarter 2021 financial results and update conference call. The news release became available just after 4:00 PM today and can be found on our website at www.caratherapeutics.com. You may also listen to a live webcast and replay of today s call on the Investors section of the website.
Before we begin, let me remind you that statements made on today s call regarding matters that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements, include statements concerning the expected timing of the data readouts from the company s planned and ongoing clinical trials, the potential results of ongoing clinical trials, timing of future regul